Product Availability: In Stock (delivery within 2-3 business days, no extra charge for drop-shipping).
Ordering: To place an order via credit card or PO use Add to Cart button (creating an account is not required).
Transfection Reagent for HepG2 Cells (Hepatocellular Carcinoma Cells, HB-8065)
Transfection Efficiency:
Reagent exhibits at least 90% transfection efficiency of siRNA delivery. Transfection efficiency was determined by qRT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems HepG2 Transfection Protocol: [PDF]
Download MSDS: [PDF]
HepG2 Cell Line:
Liver cancer is highly aggressive and devastating disease that features several main characteristics, including a high rate of recurrence, low early detection rate and ineffective treatment approaches. In addition to being the fifth common malignancy, it is considered the second primary cause of cancer-related mortalities worldwide, as stated by Oncotarget, published in July 2015. The HepG2 hepatoma cell line is important for the toxicological assessment of novel combinatorial drugs. HepG2 was derived from the liver tissue of a 15-year-old male with differentiated hepatocellular carcinoma. These cells are epithelial and have a model chromosome number of 55. HepG2 cells secrete a variety of major plasma proteins, including albumin, transferrin, alpha 1-antitrypsin, alpha 2-macroglobulin, and plasminogen (they have been grown successfully in large-scale cultivation systems). The cells are responsive to stimulation with human growth hormone. HepG2 cells have also been shown to be resistant to G418. HepG2 cells and their derivatives are used as a model system for studies of liver metabolism and toxicity of xenobiotics, antigenotoxic and cogenotoxic agents, understanding hepatocarcinogenesis, the detection of cytoprotective, and for drug targeting studies. Also, HepG2 cells are commonly employed in trials with bio-artificial liver devices. This cell line is widely used in human cancer research of the liver and is essential for many different types of biomedical research. Altogen Biosystems offers highly efficient transfection reagent kits for the HepG2 hepatoma cell line.
Data:
Figure 1. GAPD mRNA levels were quantified using real-time RT-PCR in the HepG2 cells transfected with siRNAs targeting GAPD or non-silencing siRNA. Forty-eight hours post-transfection, the cells were harvested and analyzed by real-time RT-PCR for GAPDH mRNA expression levels. Data were normalized against the 18S rRNA signal. Control samples were either mock-transfected or untreated. Values are normalized to untreated sample. Data are means ± SD (n=3).
Figure 2. Protein expression of GAPDH in HepG2 cells. DNA plasmid expressing GAPDH or siRNA targeting GAPDH were transfected into HepG2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Selected HepG2 transfection reagent product citations:
Selected in vivo transfection product citations (ALTOGEN® IN VIVO Transfection Kits used in the following publications):
Altogen Biosystems:
Altogen Biosystems is a life sciences company that manufactures over 100 cell type specific and pre-optimized transfection kits, electroporation buffers, and targeted in vivo delivery kits and reagents. Advanced formulation of reagents and optimized transfection protocols provide highly efficient intracellular delivery of biomolecules (proteins, DNA, mRNA, shRNA and siRNA, and small molecule compounds). Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for pre-clinical research, IND applications, and drug development. Biology CRO services include: Xenograft models (30+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
Volume Options:
Altogen Biosystems是一家开发和制造用于生命科学研究,药物发现和开发的转染试剂盒的生物技术公司。转染试剂盒针对特定癌细胞系和原代细胞培养进行了优化,可将生物分子有效递送到靶组织中。通过先进的试剂配方和优化的转染方案实现体外(癌细胞系)和体内(动物组织靶向试剂、癌细胞系)递送货物分子,包括质粒DNA,各种类型的RNA(mRNA,siRNA,shRNA,microRNA),蛋白质和小分子研究。
苏州蚂蚁淘代理Altogen Biosystems在中国的业务。Altogen Biosystems北京代理,Altogen Biosystems华东代理,Altogen Biosystems华北代理,Altogen Biosystems全国代理,Altogen Biosystems华南代理。